<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01280617</url>
  </required_header>
  <id_info>
    <org_study_id>2010-065</org_study_id>
    <nct_id>NCT01280617</nct_id>
  </id_info>
  <brief_title>Low Dose Thymoglobin in Renal Transplant Patients</brief_title>
  <official_title>Low Dose Thymoglobulin As Induction Agent on Prednisone-Free Regimens of Renal Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lahey Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lahey Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a planned single center prospective randomized study evaluating the safety and&#xD;
      efficacy of low dose thymoglobulin as induction agent in renal transplant recipients.&#xD;
      Inclusion criteria will be adult renal transplant recipients who are not sensitized against&#xD;
      their potential donors. The patients who agree to participate in the study will be randomly&#xD;
      assigned to either thymoglobulin at 1.25mg/kg x 3 doses or 0.75mg/kg x 3 doses. There will be&#xD;
      86 sealed envelopes to perform the randomization process. 43 envelopes with 1.25mg/kg dosing&#xD;
      and the other 43 envelopes with 0.75mg/kg dosing. The investigators will sequentially choose&#xD;
      the sealed envelopes at the time of the patient randomization process. All patients will be&#xD;
      started on our standard immunosupression regimen of prograf/cellcept and a fast steroid&#xD;
      taper. Data will be obtained from every patient for up to one year post-transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Study Design:&#xD;
&#xD;
      This is a planned single center prospective randomized study evaluating the safety and&#xD;
      efficacy of low dose thymoglobulin as induction agent in renal transplant recipients.&#xD;
      Inclusion criteria will be adult renal transplant recipients who are not sensitized against&#xD;
      their potential donors. The patients who agree to participate in the study will be randomly&#xD;
      assigned to either thymoglobulin at 1.25mg/kg x 3 doses or 0.75mg/kg x 3 doses. There will be&#xD;
      86 sealed envelopes to perform the randomization process. 43 envelopes with 1.25mg/kg dosing&#xD;
      and the other 43 envelopes with 0.75mg/kg dosing. The investigators will sequentially choose&#xD;
      the sealed envelopes at the time of the patient randomization process. All patients will be&#xD;
      started on our standard immunosupression regimen of prograf/cellcept and a fast steroid&#xD;
      taper. Data will be obtained from every patient for up to one year post-transplant.&#xD;
&#xD;
      The investigators will obtain the following information at the time of consent:&#xD;
&#xD;
        1. Type of renal transplant (living vs cadaveric)&#xD;
&#xD;
        2. HLA matching&#xD;
&#xD;
        3. CMV status of donor and recipient&#xD;
&#xD;
        4. EBV status of donor and recipient&#xD;
&#xD;
        5. Creatinine prior to transplantation&#xD;
&#xD;
        6. Urinalysis at the time of transplantation&#xD;
&#xD;
        7. Primary renal disease&#xD;
&#xD;
        8. Weight of the renal transplant&#xD;
&#xD;
        9. BMI of the recipient and donor&#xD;
&#xD;
       10. Age of the donor and recipient&#xD;
&#xD;
       11. Sex of the donor and recipient&#xD;
&#xD;
       12. White blood cell count&#xD;
&#xD;
       13. Hemoglobin&#xD;
&#xD;
       14. Platelets&#xD;
&#xD;
       15. History of infections&#xD;
&#xD;
       16. History of malignancies&#xD;
&#xD;
      During each of the clinic visits the investigators will obtain the following information:&#xD;
&#xD;
        1. Creatinine&#xD;
&#xD;
        2. Urinalysis&#xD;
&#xD;
        3. White blood cell count&#xD;
&#xD;
        4. Hemoglobin&#xD;
&#xD;
        5. Platelets&#xD;
&#xD;
        6. Weight of the recipient&#xD;
&#xD;
        7. Infections&#xD;
&#xD;
        8. Malignancies&#xD;
&#xD;
        9. Renal biopsy report if a biopsy was performed&#xD;
&#xD;
      In addition to the standard of care laboratories, the investigators will ask patients to give&#xD;
      us 7 additional green tubes, one purple tube and two red tubes which will be drawn at the&#xD;
      time of standard of care laboratories pre-transplantation, 3 months post-transplant, 6 months&#xD;
      post-transplant and 12 months post-transplant. This tubes will be used to measure CD4, CD8,&#xD;
      CD19, CD20, CD68 cells as these are cells that are believed to be affected by the use of&#xD;
      thymoglobulin.&#xD;
&#xD;
      If the patient is to have a renal transplant biopsy at any time during the 12 months of the&#xD;
      study, any excess tissue may be utilized for staining of special cell markers including CD4,&#xD;
      CD8, CD19, CD20 and CD68.&#xD;
&#xD;
      Subject inclusion criteria: Potential adult renal transplant recipients&#xD;
&#xD;
      Subject exclusion criteria: Sensitized renal transplant recipients&#xD;
&#xD;
      Methods of statistical analysis to be employed in preparation of reports:&#xD;
&#xD;
      The investigators are planning a study with 1 control per experimental subject, an accrual&#xD;
      interval of 24 time units, and additional follow-up after the accrual interval of 12 time&#xD;
      units. In a previous study the median survival time on the control treatment was 36 time&#xD;
      units. If the true hazard ratio (relative risk) of control subjects relative to experimental&#xD;
      subjects is 5, the investigators will need to study 43 experimental subjects and 43 control&#xD;
      subjects to be able to reject the null hypothesis that the experimental and control survival&#xD;
      curves are equal with probability (power) .800. The Type I error probability associated with&#xD;
      this test of this null hypothesis is 0.05. T-tests will be used to compare both groups.&#xD;
&#xD;
      Thymoglobulin (rabbit antithymocyte globulin) is FDA approved for the treatment of acute&#xD;
      cellular rejection. Nevertheless, for at least the past 10 years this medication has been&#xD;
      utilized as induction agent in renal transplant recipients. This is because an induction&#xD;
      agent allows prednisone withdrawal in renal transplant recipients.&#xD;
&#xD;
      Prednisone withdrawal is extremely important in renal transplant recipients as old protocols&#xD;
      that allowed long term prednisone use compromised the long term health of renal transplant&#xD;
      recipients. Not only does prednisone increase markedly the risk of development of diabetes&#xD;
      and osteoporosis, but is also increases drastically the risk of fractures, which is a very&#xD;
      common cause of mortality in long term prednisone renal transplant recipients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of Acute Cellular Rejection Between Study Group</measure>
    <time_frame>1 year from date of transplant</time_frame>
    <description>Incidence of Biopsy Proven Acute Rejection at 1 year post transplant:</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>, &quot;Total Number of Adverse Events, Including Any Infections, Leucopenia, and Malignancy&quot;</measure>
    <time_frame>1 year from date of transplant</time_frame>
    <description>Number of individual adverse events in high versus low dose Thymoglobulin groups will be tabulated and statistical analyses performed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Acute Renal Failure</condition>
  <arm_group>
    <arm_group_label>Thymoglobulin 1.25mg/kg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The safety and efficacy of low dose Thymoglobulin (1.25mg/kg) as an induction agent in renal transplant subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thymoglobulin 0.75mg/kg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The safety and efficacy of low dose Thymoglobulin (0.75mg/kg) as an induction agent in renal transplant subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>Thymoglobulin 1.25mg/kg dose</description>
    <arm_group_label>Thymoglobulin 1.25mg/kg dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin 0.75mg/kg dose</intervention_name>
    <description>Thymoglobulin</description>
    <arm_group_label>Thymoglobulin 0.75mg/kg dose</arm_group_label>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Potential Adult Renal Transplant Patients -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Sensitized Renal Transplant Patients&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simpson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lahey Hospital &amp; Medical Ctr</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Grafals M, Smith B, Murakami N, Trabucco A, Hamill K, Marangos E, Gilligan H, Pomfret EA, Pomposelli JJ, Simpson MA, Azzi J, Najafian N, Riella LV. Immunophenotyping and efficacy of low dose ATG in non-sensitized kidney recipients undergoing early steroid withdrawal: a randomized pilot study. PLoS One. 2014 Aug 11;9(8):e104408. doi: 10.1371/journal.pone.0104408. eCollection 2014.</citation>
    <PMID>25111080</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 19, 2011</study_first_submitted>
  <study_first_submitted_qc>January 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2011</study_first_posted>
  <results_first_submitted>September 11, 2020</results_first_submitted>
  <results_first_submitted_qc>February 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 16, 2021</results_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Transplant</keyword>
  <keyword>Thymoglubulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All unsensitized renal transplant recipients were considered eligible and were approached for consent. Inclusion dates were October 2010 until April 2013. A total of 58 patients were approached; 44 consented and were enrolled in the protocol</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Thymoglobulin 1.25mg/kg Dose</title>
          <description>The safety and efficacy of low dose Thymoglobulin (1.25mg/kg) as an induction agent in renal transplant subjects.&#xD;
Thymoglobulin: Thymoglobulin 1.25mg/kg dose</description>
        </group>
        <group group_id="P2">
          <title>Thymoglobulin 0.75mg/kg Dose</title>
          <description>The safety and efficacy of low dose Thymoglobulin (0.75mg/kg) as an induction agent in renal transplant subjects.&#xD;
Thymoglobulin 0.75mg/kg dose: Thymoglobulin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Thymoglobulin 1.25mg/kg Dose</title>
          <description>The safety and efficacy of low dose Thymoglobulin (1.25mg/kg) as an induction agent in renal transplant subjects.&#xD;
Thymoglobulin: Thymoglobulin 1.25mg/kg dose</description>
        </group>
        <group group_id="B2">
          <title>Thymoglobulin 0.75mg/kg Dose</title>
          <description>The safety and efficacy of low dose Thymoglobulin (0.75mg/kg) as an induction agent in renal transplant subjects.&#xD;
Thymoglobulin 0.75mg/kg dose: Thymoglobulin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>males</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>females</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rates of Acute Cellular Rejection Between Study Group</title>
        <description>Incidence of Biopsy Proven Acute Rejection at 1 year post transplant:</description>
        <time_frame>1 year from date of transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thymoglobulin 1.25mg/kg Dose</title>
            <description>Thymoglobulin 1.25mg/kg dose All Cause mortality 0/23</description>
          </group>
          <group group_id="O2">
            <title>Thymoglobulin 0.75mg/kg Dose</title>
            <description>Thymoglobulin 0.75mg/kg dose All Cause Mortality 3/20 - 2 with pre-existing cardiac disease, diabetes, and history of smoking</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of Acute Cellular Rejection Between Study Group</title>
          <description>Incidence of Biopsy Proven Acute Rejection at 1 year post transplant:</description>
          <units>Number of rejection</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Continuous variables analyzed using 2-tailed t test or Mann Whitney tes.. Categorical variables analyzed using Chi-Square or Fisher's Exact test</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>, &quot;Total Number of Adverse Events, Including Any Infections, Leucopenia, and Malignancy&quot;</title>
        <description>Number of individual adverse events in high versus low dose Thymoglobulin groups will be tabulated and statistical analyses performed</description>
        <time_frame>1 year from date of transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thymoglobulin 1.25mg/kg Dose</title>
            <description>Thymoglobulin 1.25mg/kg dose All Cause mortality 0/23</description>
          </group>
          <group group_id="O2">
            <title>Thymoglobulin 0.75mg/kg Dose</title>
            <description>Thymoglobulin 0.75mg/kg dose All Cause Mortality 3/20 - 2 with pre-existing cardiac disease, diabetes, and history of smoking</description>
          </group>
        </group_list>
        <measure>
          <title>, &quot;Total Number of Adverse Events, Including Any Infections, Leucopenia, and Malignancy&quot;</title>
          <description>Number of individual adverse events in high versus low dose Thymoglobulin groups will be tabulated and statistical analyses performed</description>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day of kidney transplant until end of first post transplant year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Thymoglobulin 1.25mg/kg Dose</title>
          <description>Thymoglobulin 1.25mg/kg dose All Cause mortality 0/23</description>
        </group>
        <group group_id="E2">
          <title>Thymoglobulin 0.75mg/kg Dose</title>
          <description>Thymoglobulin 0.75mg/kg dose All Cause Mortality 3/20 - 2 with pre-existing cardiac disease, diabetes, and history of smoking</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Serious Infections</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Delayed Graft Function</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mary Ann Simpson, Ph.D</name_or_title>
      <organization>Lahey Hospital &amp; Medical Ctr</organization>
      <phone>781-744-2500</phone>
      <email>Mary.a.Simpson@Lahey.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

